#United States #San Francisco #Healthcare Conference #Rivus Pharmaceuticals #HU6

Rivus Pharmaceuticals to Present Key Updates at J.P. Morgan Healthcare Conference 2025

Rivus Pharmaceuticals, Inc. is gearing up to present its latest corporate updates at the prestigious 2025 J.P. Morgan Healthcare Conference. This biopharmaceutical company, known for its focus on treating cardiometabolic diseases related to obesity, has announced that Jayson Dallas, M.D., the CEO, will lead a presentation outlining pivotal advancements in their research pipeline.

The company is set to unveil significant information regarding their experimental therapies known as Controlled Metabolic Accelerators (CMAs). This innovative class of treatments aims to enhance metabolic health among individuals struggling with obesity and associated conditions. A focal point of the presentation will be updates pertaining to HU6, the company's flagship investigational drug. HU6 is a once-daily oral medication designed to promote effective body fat loss while maintaining muscle mass by increasing the resting metabolic rate.

Recently, Rivus completed a six-month active dosing phase in the Phase 2 clinical trial named M-ACCEL, which includes 220 patients diagnosed with metabolic dysfunction associated with fatty liver disease, commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH). Topline data from M-ACCEL is expected to be released in the second quarter of 2025, marking the third Phase 2 study completion for HU6, underlining the drug's extensive clinical evaluation.

Dr. Dallas emphasized the gravity of the obesity epidemic, which underpins numerous chronic illnesses claiming more lives annually than all types of cancer combined. He stated, "We believe that HU6 and our CMA portfolio could play a crucial role in transforming care for patients suffering from obesity-related diseases while ensuring the preservation of lean body mass." As a testament to the drug's efficacy, HU6 has already been administered to over 400 patients from diverse backgrounds, showcasing Rivus's commitment to addressing these pressing health issues.

Presentation Details

The presentation is scheduled for January 13, 2025, at 8:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Rivus will feature in the private company track, emphasizing the importance of this conference for the biopharmaceutical community.

Understanding Controlled Metabolic Accelerators (CMAs)

Rivus’s CMAs represent a novel therapeutic approach to combat obesity and related metabolic disorders. These oral small molecules are designed to increase resting metabolic rates, elevating energy consumption primarily from fat reserves. The mechanism behind CMAs utilizes a process known as mitochondrial uncoupling, ensuring that metabolic enhancement occurs subtly and without noticeable side effects for the user. Initial clinical findings suggest that CMAs can facilitate selective fat loss, enhancing insulin sensitivity while simultaneously reducing oxidative stress and inflammation.

Spotlight on HU6

The proprietary HU6 stands out as Rivus's lead CMA. This investigational small molecule targets key metabolic diseases intertwined with cardiac, liver, and Type 2 diabetes complications. The drug aims to significantly increase metabolism imperceptibly, promoting body fat reduction while safeguarding muscle mass. Clinical trials have illustrated substantial improvements in liver fat percentage and systemic inflammation markers among patients with elevated body mass index (BMI) and metabolic dysfunction.

In phase 2 studies, HU6 reported significant reductions in visceral fat and body weight, showcasing its potential as an impactful therapy for patients suffering from obesity-related heart failure with preserved ejection fraction (HFpEF) and other metabolic liver diseases.

As Rivus Pharmaceuticals continues to push the boundaries of innovation in the treatment of cardiometabolic diseases, this forthcoming conference presentation promises to deliver critical insights and future directions for the company's groundbreaking work.

For additional information, visit Rivus Pharmaceuticals' website.